Analysis of survival period and efficacy of long-term use of Lynparza

Olaparib is an oral PARP inhibitor, mainly used to treat solid tumors such as ovarian cancer, breast cancer, pancreatic cancer and prostate cancer related to BRCA1/2 mutations. Its mechanism of action is to inhibit the activity of polyADPribose polymerase (PARP), hinderDNA single-strand repair, induce the accumulation of tumor cellDNA damage, and ultimately lead to cancer cell apoptosis. Compared with traditional chemotherapy, olaparib is more selective and less toxic to normal cells, making it suitable for long-term maintenance treatment.

Multiple clinical studies have shown that long-term use of olaparib can significantly extend patients’ progression-free survival (PFS) and overall survival (OS). In patients with BRCA mutation-positive recurrent ovarian cancer, the PFS of maintenance therapy can be extended to 19 to 21 months, compared with 5 u200bu200bto 10 months in the control group. Long-term use not only inhibits tumor recurrence, but also stabilizes disease progression and provides patients with more treatment windows. At the same time, long-term use allows some patients to remain sensitive to other subsequent treatments when they relapse, improving overall survival benefit.

The efficacy of olaparib is not only reflected in prolonged survival, but also in improved tumor burden and quality of life. During long-term maintenance treatment, the tumor size of most patients significantly reduced or remained stable, and some patients even experienced complete remission (CR). Compared with traditional chemotherapy, the side effects of olaparib are relatively controllable. Common adverse reactions include anemia, nausea, fatigue and mild thrombocytopenia, and most of them can be alleviated through dose adjustment or symptomatic treatment. Therefore, long-term use can not only ensure the curative effect, but also maintain a better quality of life.

In actual clinical practice, olaparib is suitable for maintenance treatment of recurrent tumors and long-term management of BRCA positive patients. Patients need to regularly monitor blood routine and liver and kidney function during use in order to detect and deal with adverse reactions in a timely manner. For patients who tolerate it well, it is recommended to take the medication regularly to achieve full long-term efficacy. Overall, long-term use of olaparib can significantly extend survival and delay tumor recurrence, and is an important maintenance treatment option for patients with BRCA mutation-related tumors.

Reference materials:https://www.drugs.com/